ARDS (ARDS) Stock Price & Analysis
ARDS (ARDS) rose 0.00% to USD 0 as of June 10, 2026 at 03:31 UTC, according to Nexqual real-time market data.
ARDS last closed at USD 0; the session ranged USD 0–0 on volume of 10 shares. Market capitalization is $8,914, with a 52-week range of USD 0–0.05 (PNK). Source: Nexqual, June 10, 2026 at 03:31 UTC.
Key Statistics (as of June 10, 2026 at 03:31 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0.05 |
| Volume | 10 shares |
| Market Cap | $8,914 |
| Exchange | PNK |
Technical Analysis (ARDS)
Nexqual's technical model rates ARDS "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:31 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 47.7 (neutral) |
| vs SMA50 | Below (USD 0) |
| MACD | -0 (negative) |
Analyst Ratings (ARDS)
Wall Street analysts rate ARDS "None", per Nexqual as of June 10, 2026 at 03:31 UTC.
| Consensus Rating | None |
|---|
Earnings (ARDS)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-09-30 | USD 0 vs est -0.1 ▲ beat |
| 2022-12-31 | USD -0.5 vs est -0.41 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:31 UTC.
Financials & Fundamentals (ARDS)
| Total Revenue | $22.36M |
|---|---|
| Revenue Growth (YoY) | +4.50% |
| Gross Margin | +23.28% |
| Operating Margin | -208.39% |
| Profit Margin | -5.11% |
| Current Ratio | 0.24 |
| Total Cash | $35,000 |
| Total Debt | $4.84M |
| Free Cash Flow | $-16.39M |
Source: Nexqual, June 10, 2026 at 03:31 UTC.
Financial Health Score (ARDS)
Nexqual rates ARDS's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:31 UTC.
| Growth | Strong — Revenue +101% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $35K cash vs $5M debt |
| Cash Flow | Weak — FCF negative: -$16M, burning cash |
| Efficiency | Mixed — No data |
Ownership (ARDS)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +11.44% |
| Shares Outstanding | 44.57M |
| Float | 40.31M |
| Short % of Float | +6.80% |
Source: Nexqual, June 10, 2026 at 03:31 UTC.
Leadership (ARDS)
ARDS is led by Vu L. Truong (age 61), Founder, CEO, Chief Scientific Officer & Director, per Nexqual as of June 10, 2026 at 03:31 UTC.
| Founder, CEO, Chief Scientific Officer & Director | Vu L. Truong (age 61) |
|---|---|
| Founder & Executive Chairman | Eric J. Patzer (age 76) |
Major Backers & Investors (ARDS)
Notable institutional backers of ARDS include Starboard Investment Tr-Roumell Opportunistic Value Fd, according to Nexqual as of June 10, 2026 at 03:31 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Starboard Investment Tr-Roumell Opportunistic Value Fd | 0.84% |
Source: Nexqual, June 10, 2026 at 03:31 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATXI | Avenue Therapeutics, Inc. | USD 0.36 | ▲ 2.27% |
| EVLO | Evelo Biosciences, Inc. | USD 0 | ▲ 200% |
| GRTX | Galera Therapeutics, Inc. | USD 0.09 | ▼ 2.11% |
| KRBPQ | Kiromic BioPharma, Inc. | USD 0 | ▲ 0% |
| ADIL | Adial Pharmaceuticals, Inc | USD 2.13 | ▼ 3.62% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:31 UTC. This page is informational and not investment advice.